Current Liabilities

Other accrued liabilities

United Therapeutics Other accrued liabilities increased by 38.8% to $100.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.8%, from $154.50M to $100.80M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 12.9% CAGR.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ3 2025
Last reportedQ1 2026

How to read this metric

Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.

Detailed definition

This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...

Peer comparison

Commonly used as a catch-all for short-term liabilities; varies by industry and business model.

Metric ID: current_liabilities_other_liabilities_current

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$24.80M$26.00M$28.40M$60.80M$39.60M$35.70M$32.50M$38.60M$37.80M$70.10M$71.00M$126.30M$77.80M$80.10M$93.60M$154.50M$95.10M$78.30M$72.60M$100.80M
QoQ Change+4.8%+9.2%+114.1%-34.9%-9.8%-9.0%+18.8%-2.1%+85.4%+1.3%+77.9%-38.4%+3.0%+16.9%+65.1%-38.4%-17.7%-7.3%+38.8%
YoY Change+59.7%+37.3%+14.4%-36.5%-4.5%+96.4%+118.5%+227.2%+105.8%+14.3%+31.8%+22.3%+22.2%-2.2%-22.4%-34.8%
Range$24.80M$154.50M
CAGR+34.3%
Avg YoY Growth+40.6%
Median YoY Growth+22.3%

Frequently Asked Questions

What is United Therapeutics's other accrued liabilities?
United Therapeutics (UTHR) reported other accrued liabilities of $100.80M in Q1 2026.
How has United Therapeutics's other accrued liabilities changed year-over-year?
United Therapeutics's other accrued liabilities decreased by 34.8% year-over-year, from $154.50M to $100.80M.
What is the long-term trend for United Therapeutics's other accrued liabilities?
Over 5 years (2020 to 2025), United Therapeutics's other accrued liabilities has grown at a 12.9% compound annual growth rate (CAGR), from $39.50M to $72.60M.
What does other accrued liabilities mean?
Miscellaneous short-term debts or obligations not covered by other standard categories.